 SAN DIEGO, July 29, 2021 GLOBE NEWSWIRE -- Crinetics Pharmaceuticals, Inc. Nasdaq: CRNX, a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has entered into a securities purchase agreement with Frazier Healthcare Partners for the private placement of 851,306 shares at 17.62 per share. The private placement will yield gross proceeds of 15.0 million and is expected to close on August 2, 2021, subject to the satisfaction of customary closing conditions. 